Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus — Stella

Home/Systemic Lupus Erythematosus (SLE)/Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

View on ClinicalTrials.gov

Recruiting

Back to Systemic Lupus Erythematosus (SLE) trials

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Excyte Biopharma Ltd

Enrollment target

~189 participants

Started

August 2025

Primary completion

June 2027

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.